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Abstract 
Bryophyllum pinnatum is a succulent perennial plant native to Madagascar which is used in 
anthroposophical medicine to treat psychiatric disorders, and as a tocolytic agent to prevent premature 
labour. We performed a metabolite profiling study in order to obtain a comprehensive picture of the 
constituents in B. pinnatum leaves, and to identify chromatographic markers for quality control and safety 
assessment of medicinal preparations. Preliminary HPLC-PDA-ESIMS analyses revealed that flavonoid 
glycosides were the main UV-absorbing constituents in the MeOH extract of B. pinnatum. Two phenolic 
glucosides, syringic acid β-D-glucopyranosyl ester (1) and 4’-O-β-D-glucopyranosyl-cis-p-coumaric acid 
(2), as well as nine flavonoids (3-11) including kaempferol, quercetin, myricetin, acacetin, and diosmetin 
glycosides were unambiguously identified by 1H and 2D NMR analysis after isolation from a MeOH 
extract. The flavonol glycosides quercetin 3-O-α-L-arabinopyranosyl-(1  2)-α-L-rhamnopyranoside 7-
O-β-D-glucopyranoside (3) and myricetin 3-O-α-L-arabinopyranosyl-(1  2)-α-L-rhamnopyranoside (4) 
were new natural products. With the aid of HPLC-PDA-APCIMS and authentic references isolated from 
the related species B. daigremontianum, the presence of four bufadienolides, bersaldegenin-1-acetate 
(12), bryophyllin A (13), bersaldegenin-3-acetate (14), and bersaldegenin-1,3,5-orthoacetate (15) was 
detected in B. pinnatum. 
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Abbreviations: 
APCI: Atmospheric-pressure chemical ionization 
ESI: Electrospray ionization 
PDA: Photodiode array 
 
Introduction 
Bryophyllum pinnatum (Lam.) Oken (syn. Kalanchoe pinnata Pers., Bryophyllum calycinum Salisb.) is a 
succulent perennial plant native to Madagascar and belongs to the family of Crassulaceae. It is commonly 
known as Life plant, Air plant, Love plant, and Goethe plant. B. pinnatum has been widely used in 
traditional medicine, especially in Madagascar, Indonesia, India, Nigeria, Trinidad and Tobago where the 
leaves have been utilized to treat jaundice [1], skin diseases, urinary problems, hypertension, and for its 
cooling properties in topical use [2-4]. 
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In 1921, B. pinnatum preparations were established by Rudolf Steiner as anthroposophical medicines to 
treat hysteria [5]. Later, B. pinnatum was also used in obstetrics and gynaecology as a tocolytic agent to 
prevent premature labour [6] and, more recently, to treat sleep disorders in pregnancy. As a tocolytic 
agent B. pinnatum showed only mild and few adverse effects and was very well tolerated [7]. We could 
show that the leaf juice inhibits oxytocin-induced increase of intracellular calcium concentration in 
human myometrial cells [8] and induces myometrial relaxation in vitro [9]. Recently, we reported that B. 
pinnatum leaf press juice also inhibits porcine detrusor contractility in vitro [10]. To explore the potential 
of B. pinnatum as a treatment for patients suffering from overactive bladder syndrome, a pilot study in 
humans was performed. A positive trend for a B. pinnatum preparation compared to placebo could be 
shown [11]. 
With respect to pharmacological properties of B. pinnatum, antileishmanial [12], antiulcer [13], 
antibacterial [14,15], antitumor promoting [16], immunosuppressive [17], and antihypertensive effects 
[18] have been reported. Compounds identified in the plant include flavonoids, triterpenes, phytosterols, 
bufadienolides, fatty acids, and minerals [19]. The flavonoid fraction was found to consist mainly of 
kaempferol and quercetin glycosides, some of which have shown in vitro antileishmanial activity [12,20]. 
A series of bufadienolides such as bryophyllins A - C, and bersaldegenin derivatives have been isolated 
[19,21]. These compounds reportedly possess sedative and positive inotropic properties, as well as central 
nervous system (CNS) related activities [22]. For safety assessment and quality control of phytomedicines 
containing B. pinnatum, detailed information on the metabolite profile of is required. There have been 
only few relevant analytical studies on B. pinnatum. Four flavonoids were assigned in the HPLC-UV-MS 
chromatogram of an aqueous extract [23].  A series of flavonoids were also identified by HPLC-UV in a 
chromatographic fraction.  [24]. No study includes, however, a comprehensive analysis of the constituents 
of the plant. We therefore conducted a metabolite profiling of the MeOH extract in order to identify 
useful chromatographic markers for quality control and safety assessment, whereby special emphasis was 
put on flavonoids and bufadienolides.  
 
Results and Discussion 
To obtain a comprehensive metabolite profile, leaves of B. pinnatum were extracted with MeOH, and the 
extract submitted to HPLC-PDA-ESIMS analysis (Fig. 1). The UV trace and PDA spectra revealed the 
presence of several peaks of UV-absorbing phenolic compounds. In addition, a group of large peaks 
eluting between 19 and 24 min were detected in the MS trace. By comparison with reference compounds 
previously isolated by the authors from Lycium barbarum (unpublished results), two peaks at tR 22.0 min 
(m/z 520.6 [M]+) and tR 23.2 min (m/z 496.6 [M]+) were assigned to linoleoyl lysophosphatidylcholine, 
and palmitoyl lysophosphatidylcholine, respectively. In addition, a peak at tR 20.4 min (m/z 518.6) was 
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tentatively assigned to -linolenoyl lysophosphatidylcholine. Most peaks detected in the UV trace could 
be identified after targeted purification by a combination of Sephadex LH-20 and Diaion HP-20 column 
chromatography, and preparative and semi-preparative HPLC. The structures were established on the 
basis of UV, 1H and 13C NMR spectra, and by comparison with literature data. 
Compounds 1 (m/z 743.2 [2M + H]+) and 2 (m/z 651.2 [2M - H]-, 325.2 [M - H]-) were shown to be 
phenolic acid derivatives. They were identified as syringic acid β-D-glucopyranosyl ester (1) [25] and 4’-
O-β-D-glucopyranosyl-cis-p-coumaric acid (2) [26]. The cis-configuration of the olefinic double bond in 
2 is supported by the 3JHH-coupling constant of the corresponding protons (H-2 δH 5.85 ppm, H-3 δH 6.53 
ppm, J = 12 Hz). 
Compounds 3-11 exhibited UV spectra characteristic for flavonoids. Their structures (Fig. 2) were 
assigned by ESIMS, NMR, and by comparison with literature data. Compounds 6 (m/z 581.3 [M + H]+, 
449.2 [(M + H) - 132]+, 303.2 [(M + H) - 132 - 146]+ ) and 8 (m/z 449.2 [M + H]+, 303.2 [(M + H) - 
146]+) were quercetin glycosides. They were identified as quercetin 3-O-α-L-arabinopyranosyl-(1  2)-
α-L-rhamnopyranoside (6) [12], and quercitrin (quercetin 3-O-α-L-rhamnopyranoside, 8) [20], 
respectively. Compound 5 (m/z 465.1 [M + H]+, 319.2 [(M + H) - 146]+) was identified as myricitrin 
(myricetin 3-O-α-L-rhamnopyranoside, 5) [27]. Compounds 9 (m/z 565.3 [M + H]+, 433.2 [(M + H) - 
132]+, 287.2 [(M + H) - 132 - 146]+) and 10 (m/z 565.3 [M + H]+, 433.2 [(M + H) - 132]+, 287.2 [(M + H) 
- 132 - 146]+) were shown to be kaempferol glycosides, namely kaempferol 3-O-α-L-arabinopyranosyl-(1 
 2)-α-L-rhamnopyranoside (9) [12] and kaempferol 3-O-β-D-xylopyranosyl-(1  2)-α-L-
rhamnopyranoside (10) [28], respectively. Compounds 7 (m/z 609.4 [M + H]+) and 11 (m/z 593.4 [M + 
H]+) were identified as diosmine (diosmetin 7-O-α-L-rhamnopyranosyl-(1  6)-β-D-glucopyranoside, 7) 
[29] and acacetin 7-O-α-L-rhamnopyranosyl-(1  6)-β-D-glucopyranoside (11) [30], respectively. The 
position of the sugar residues and the interglycosidic linkages in all compounds were supported by 
HMBC correlations. 1H and 13C NMR data are provided as Supporting Information.  
Compounds 3 and 4 are new flavonol glycosides. Their structures were established as follows: The 
HRESIMS spectrum of 3 showed a quasimolecular [M + Na]+ ion peak at m/z 765.1844, in agreement 
with a molecular formula of C32H38O20. Fragment ions were detected at m/z 611.3 [(M + H) - 132]+, and 
465.2 [(M + H) - 132 - 146]+. The aglycone was identified as quercetin from its NMR data (Table 1) and 
by comparison with compounds 6 and 8. Acid hydrolysis afforded D-glucose, L-rhamnose and L-
arabinose. The monosaccharides were identified by GC-MS analysis after derivatization with L-cysteine 
methyl ester and silylation. The α-configuration of the arabinopyranosyl, and the -configuration of the 
glucopyranosyl residues were derived from the coupling constant of the anomeric protons at δH 4.16 (d, 
5.9 Hz, H-1’’’) and δH 5.06 ppm (d, 6.9 Hz, H-1’’’’), respectively. The -configuration of the 
rhamnopyranosyl residue was assigned by 13C NMR [12]. The NMR data of the disaccharide moiety were 
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in full agreement with those recorded for compound 6. The interglycosidic linkage was confirmed by an 
HMBC correlation between H-1’’’ (δH 4.16 ppm) of the α-L-arabinopyranosyl moiety and C-2’’ (δC 80.1) 
of the α-L-rhamnopyranosyl residue. The HMBC correlation between H-1’’ of the rhamnosyl moiety (δH 
5.36) and C-3 of the aglycone (δC 135.0) revealed the attachment of the disaccharide moiety. The 
attachment of the β-D-glucopyranosyl moiety at C-7 was established by NOESY contacts of the anomeric 
proton H-1’’’’ with H-6 and H-8. The structure of 3 was thus established as quercetin 3-O-α-L-
arabinopyranosyl-(1  2)-α-L-rhamnopyranoside 7-O-β-D-glucopyranoside. 
A molecular formula of C26H28O16 for compound 4 was established by HRESIMS spectroscopy ([M + 
Na]+ quasimolecular ion at m/z 619.1290). Fragment ions were observed at m/z 465.2 [(M + H) - 132]+, 
and 319.2 [(M + H) - 132 - 146]+ in the ESIMS spectrum. The NMR data (Table 2) of the disaccharide 
moiety were almost identical with those of compounds 3 and 6. An HMBC correlation between H-1’’ of 
rhamnose (δH 5.23) and C-3 of the aglycone (δC 135.0) indicated the attachment of the sugar moiety. 
Compound 4 differed from 6 only in the substitution of the B-ring. A signal corresponding to two protons 
appeared as singulet at H 6.93 ppm. The NMR data of the aglycone were in full agreement with those of 
compound 5, confirming the aglycone to be myricetin. Compound 4 was thus myricetin 3-O-α-L-
arabinopyranosyl-(1  2)-α-L-rhamnopyranoside. Among the isolated compounds, only the quercetin 
glycosides 6 and 8, as well as the kaempferol glycoside 9 were previously identified in B. pinnatum [12]. 
Occurrence of bufadienolides in B. pinnatum has been reported [31], but we could not detect them by 
HPLC-PDA-ESIMS analysis of the MeOH extract. For targeted chromatographic detection, reference 
compounds were isolated from a related species, B. daigremontianum, known to contain higher 
concentrations of bufadienolides. Compounds 12-15 were obtained from the CH2Cl2-soluble fraction of 
the MeOH extract by a combination of preparative and semi-preparative HPLC on RP-18. They were 
identified as bersaldegenin-1-acetate (12, m/z 475.4 [M + H]+) [22], bryophyllin A (13, m/z 473.4 [M + 
H]+) [32], bersaldegenin-3-acetate (14, m/z 475.5 [M + H]+) [22], and bersaldegenin-1,3,5-orthoacetate 
(15, m/z 457.3 [M + H]+) [22] by APCIMS, 1H and 2D NMR. 1H and 13C NMR data of 12-15 are 
provided as Supporting Information, and their structures are shown in Fig. 3. 
Using the reference compounds 12-15 isolated from B. daigremontianum, the presence of bufadienolides 
in B. pinnatum was confirmed by HPLC-APCIMS. The four bufadienolides 12-15 could be detected in 
the CH2Cl2-soluble fraction of the MeOH extract of B. pinnatum (Fig. 4). To the best of our knowledge, 
bersaldegenin-1-acetate (12) had not been previously reported as constituent of B. pinnatum, while 
compounds 13-15 were already described [33]. It is noteworthy that bufadienolides 12-15 could not be 
detected by HPLC-ESIMS in positive or negative ion mode under these conditions.  
In conclusion, our study provides a detailed metabolite profile of the leaves of B. pinnatum. Two phenolic 
acids, several flavonol and O-methylated flavone glycosides, a bufadienolide, and 
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lysophosphatidylcholine derivatives were identified for the first time in this plant which is currently the 
object of clinical investigations in different therapeutic indications [10,11]. Two flavonol glycosides were 
new natural products. Most peaks detected by HPLC-PDA-ESIMS could be structurally assigned. In 
addition, bufadienolides could be unambiguously detected by HPLC-APCIMS. In agreement with 
previous reports, flavonoids are the main UV-active constituents of the MeOH leaf extract. The major 
peak was found to be quercetin 3-O-α-L-arabinopyranosyl-(1  2)-α-L-rhamnopyranoside (6), 
confirming a previous report of its occurence as the main flavonoid in an aqueous extract [23]. The 
flavonoids identified are suited as chemical markers for quality control of medicinal preparations, 
whereas the bufadienolides are important for safety assessment regarding the presence or absence of 
potentially toxic constituents in specific products. 
 
	
Material and methods 
 
General experimental procedures 
Solvents were from Scharlau. Technical grade solvents were used after redistillation for extraction and 
column chromatography (CC). HPLC grade solvents were used for HPLC. HPLC grade water was 
obtained by an EASY-pure II (Barnstead) water purification system. Diaion HP-20 (250 µm) was 
purchased from Supelco. Sephadex LH-20 was obtained from Pharmacia Fine Chemicals. A pump (model 
881, Büchi) and a fraction collector (Superfrac, Pharmacia Biotech) were used for CC on Sephadex LH-
20. For TLC analysis, silica gel plates F254 (10-12 µm; Merck) were used with MeOH/EtOAc (1:3) or 
CHCl3/MeOH/H2O (65:35:5) as mobile phase. Detection was at UV 254 and 366 nm, and after staining 
with vanillin/sulfuric acid reagent or Natural Product Reagent A (1% ethanolamine diphenylborate, 
Sigma-Aldrich). Silica gel plates 60F264s (5-6 µm; Merck) were used for HPTLC with 
EtOAc/HCOOH/AcOH/H2O (100:11:11:26) as mobile phase. Detection was at 366 nm after spraying 
with Natural Product Reagent A. GC-MS analysis was performed using a HP 5890 Series II gas 
chromatograph equipped with a HP 5971 mass selective detector (Hewlett Packard). HPLC-PDA-MS 
analyses were performed using an Agilent 1100 Series HPLC coupled to a Bruker Esquire 3000 plus mass 
spectrometer. Separations were performed on a C18 SunFireTM column (3.5 μm, 3 x 150 mm, Waters) 
equipped with a guard column (3 x 10 mm). The samples were dissolved in DMSO at a concentration of 3 
mg/mL (extract, fractions) or 0.6 mg/mL (pure compounds). 10 μL (fractions, compounds) or 20 μL 
(extract) were injected. The mobile phase consisted of 0.1% aqueous formic acid (A) and MeCN (B) and 
a linear gradient of 5-100% B in 30 min was applied. The flow rate was 0.5 mL/min. UV spectra were 
recorded from 210 to 400 nm. ESIMS spectra were obtained in positive and negative ion modes between 
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m/z 200 and 1500. APCIMS spectra were recorded in the positive ion mode between m/z 150 and 1500. 
Semi-preparative HPLC was carried out on an Agilent 1100 Series system connected to a PDA detector. 
Separations were performed on a Waters SunFireTM C18 column (5 µm, 10 x 150 mm) equipped with a 
precolumn (5 µm, 10 x 10 mm). The mobile phase consisted of 0.1% aqueous formic acid (A) and MeCN 
(B). The flow rate was 3 mL/min. Preparative HPLC was performed on a Shimadzu LC-8A instrument 
connected to a SPD-M10AVP PDA detector. A Waters SunFireTM C18 OBDTM column (5 μm, 30 x 
150 mm) was used for separation. The mobile phase consisted of 0.1% aqueous formic acid (A) and 
MeCN (B). The flow rate was 20 mL/min. 1H NMR and 2D NMR (COSY, HSQC, HMBC, selective 
TOCSY, HSQC-TOCSY) data were recorded in DMSO-d6 or in CDCl3 on a Bruker Avance IIITM 
500 MHz NMR spectrometer equipped with a 1 mm TXI microprobe. Data were processed with Topspin 
2.1 software (Bruker). Optical rotation was measured on a Perkin Elmer Model 341 polarimeter. UV 
spectra of 3 and 4 were recorded on a Lambda 35 spectrophotometer (Perkin Elmer). HRESIMS data 
were obtained on a MicrOTOF mass spectrometer (Bruker Daltonics). 
 
Plant material 
Bryophyllum pinnatum leaves were harvested from plants cultivated in Schwäbisch Gmünd, Germany, by 
Weleda Schwäbisch Gmünd, Germany, in July and August 2010. A voucher specimen (ZSS 29715) has 
been deposited at The Zurich Succulent Plant Collection. Bryophyllum daigremontianum leaves were 
harvested from plants grown in Arlesheim, Switzerland by Ita Wegman Hospital Arlesheim, Switzerland 
in September 2011. A voucher specimen (838) has been deposited at the Division of Pharmaceutical 
Biology, University of Basel. After harvesting, the leaves were frozen and stored at -20°C until 
processing. 
 
Extraction 
The frozen leaves of B. pinnatum and B. daigremontianum were lyophilized. The dried leaves were 
pulverized in a mortar, and the powder (B. pinnatum: 593.4 g, B. daigremontianum: 37.5 g) was extracted 
with MeOH (B. pinnatum: 6 L, B. daigremontianum: 400 mL). The suspension was stirred for 2 h and 
subsequently sonicated for additional 20 min. The extract was filtered and evaporated under reduced 
pressure to yield the MeOH extract (B. pinnatum: 53.4 g; B. daigremontianum: 7.1 g).  
 
Fractionation of B. pinnatum leaf extract 
A portion of the MeOH extract (9.0 g) was dissolved in 20 mL of MeOH, applied to a Sephadex LH-20 
column (5.5 x 100 cm i.d.) and eluted with MeOH at a flow rate of 2 mL/min. 9-min fractions were 
collected and combined based on TLC analysis to afford 10 main fractions: B1 (Fr. 1-51, 0.04 g), B2 (Fr. 
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52-67, 0.38 g), B3 (Fr. 68-79, 2.68 g), B4 (Fr. 80-97, 2.23 g), B5 (98-110, 0.17 g), B6 (111-123, 0.42 g), 
B7 (Fr. 124-146, 0.16 g), B8 (Fr. 147-165, 0.33 g), B9 (Fr. 166-196, 0.05 g), and B10 (Fr. 197-241, 0.35 
g). Based on HPTLC and HPLC-UV-ESIMS analyses, fractions B4, B6, and B8 were selected for further 
investigation. Fraction B4 (2.21 g) was separated by CC (2.5 x 41 cm i.d.) on Diaion HP-20. The sample 
was dissolved in H2O, and the column eluted successively with 750 mL of H2O and 1 L of MeOH. An 
aliquot (610 mg) of the MeOH fraction eluted from fraction B4 was separated by preparative HPLC using 
a linear gradient of 5-45% B in 30 min. The sample dissolved in DMSO (1 g/mL) was injected as 6 
aliquots to provide compounds 1 (3.6 mg, tR 11.5 min), 11 (5.5 mg, tR 25.0 min) and a mixture (3.4 mg, tR 
13.6 min) which was further separated by semi-preparative HPLC with a linear gradient of 10-30% B in 
30 min to provide compounds 2 (0.9 mg, tR 10.7 min,) and 3 (1.1 mg, tR 11.4 min). A second aliquot (506 
mg) of the same fraction was separated by semi-preparative HPLC with a linear gradient of 10-45% B in 
30 min. The sample dissolved in 1 mL DMSO was injected in 11 portions to yield compound 7 (4.9 mg, 
tR 14.3 min). Fraction B6 (390 mg) was separated by preparative HPLC with a linear gradient of 20-50% 
B for 30 min. The sample dissolved in DMSO (125 mg/mL) was injected as 3 aliquots to give compounds 
4 (2.4 mg, tR 8.2 min), 6 (71.6 mg, tR 10.0 min), 9 (11.0 mg, tR 12.0 min), and 10 (1.0 mg, tR 12.6 min). 
Fraction B8 (430 mg) was separated by preparative HPLC as 3 aliquots using the same system to result in 
compounds 5 (5.1 mg, tR 9.0 min), and 8 (2.1 mg, tR 11.4 min). 
Quercetin 3-O-α-L-arabinopyranosyl-(1  2)-α-L-rhamnopyranoside 7-O-β-D-glucopyranoside (3): 
yellow amorphous powder. UV (MeOH): max (log ): 207 (4.55), 256 (4.27), 268 (4.16), 350 (4.03); []D 
- 94 (c 0.044, MeOH); 1H and 13C NMR data (DMSO-d6): see Table 1. HRESIMS: m/z 765.1844 [M + 
Na]+ (calcd. for C32H38NaO20: 765.1849); ESIMS: m/z 743.2 [M + H]+, 611.3 [(M + H) - 132]+, 465.2 [(M 
+ H) - 132 - 146]+. 
Myricetin 3-O-α-L-arabinopyranosyl-(1  2)-α-L-rhamnopyranoside (4): yellow amorphous powder. 
UV (MeOH): max (log ): 209 (4.41), 258 (3.92), 303 (sh, 3.55), 353 (3.81); []D - 72 (c 0.069 MeOH); 
1H and 13C NMR data (DMSO-d6): see Table 2. HRESIMS: m/z 619.1290 [M + Na]+ (calcd. for 
C26H28NaO16: 619.1270); ESIMS: m/z 597.1 [M + H]+, 465.2 [(M + H) - 132]+, 319.2 [(M + H) - 132 - 
146]+. 
 
Acid hydrolysis and sugar analysis 
Compound 3 (0.5 mg) was heated at 100 °C in 2N HCl (1 mL) for 2 h. After cooling, the mixture was 
extracted with EtOAc (2 x 0.5 mL), and the aqueous phase freeze-dried. The sugars were redissolved in 
anhydrous pyridine, derivatized with L-cysteine methyl ester hydrochloride (200 L, 60 ºC, 1 h) and 
subsequently silylated with hexamethyldisilazane and chlorotrimethylsilane (Fluka) in pyridine (2:1:10; 
300 µL; 60 ºC, 30 min). GC-MS analysis was performed on a DB-225MS column (0.25 µm; 0.25 mm x 
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30 m; Agilent). The oven temperature was initially held 2 min at 150 °C, then increased to 270 °C at a 
rate of 5 °C/min, and finally kept at 240 °C for 10 min. The injector temperature was 300 °C and the 
transfer line temperature 280 °C. The He pressure was 0.8 bar and the splitting ratio 1:10. L-arabinose (tR 
13.93 min), L- rhamnose (tR 14.62 min) and D-glucose (tR 16.23 min) were identified by comparison with 
reference sugars treated under the same conditions.  
 
Isolation of bufadienolides 
A portion (4.0 g) of the MeOH extract of B. daigremontianum was partitioned between CH2Cl2 and H2O. 
The CH2Cl2 soluble fraction (0.9 g) was shown by HPLC-PDA-APCIMS analysis to contain the 
bufadienolides, and was separated by preparative HPLC using a linear gradient of 5-100% B for 30 min. 
The sample was dissolved in 4.4 mL DMSO and injected as 11 aliquots. Compounds 12 (2.2 mg, tR 13.3 
min) and 15 (4.1 mg, tR 17.8 min), and a bufadienolide mixture (1.5 mg, tR 13.9 min) were obtained. The 
latter was further separated by semi-preparative HPLC using a linear gradient of 10-80% B in 30 min. 
Compounds 13 (0.7 mg, tR 13.9 min) and 14 (0.8 mg, tR 14.2 min) were obtained. 
 
Detection of bufadienolides in B. pinnatum 
A portion of the MeOH extract (1.0 g) of B. pinnatum was partitioned between CH2Cl2 and H2O. The 
CH2Cl2 soluble fraction (80 mg) was analyzed by HPLC-PDA-APCIMS. The sample was dissolved in 
DMSO (1 mg/mL) and 20 μL was injected. Analysis was performed with a linear gradient of 5-100% B in 
30 min, at a flow rate of 0.5 mL/min. Bufadienolides 12-15 were identified by comparison with reference 
compounds isolated from B. daigremontianum. 
 
Supporting information 
1H NMR spectra of 3 and 4, as well as 1H and 13C NMR data of compounds 1, 2, and 5-15 are provided as 
Supporting Information. 
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Table 1 1H and 13C NMR data of compound 3 in DMSO-d6 
position δH (m, J in Hz) δCb),c)  positiona) δH (m, J in Hz) δCb)
Aglycone      Rha    
2 - n.d.  1‘‘ 5.36 (s) 100.9
3 - 135.0  2‘‘ 4.06 (s) 80.1
4 - n.d.  3‘‘ 3.63 (m) 70.3
5 - n.d.  4‘‘ 3.16 (m) 72.2
6 6.43 (s) 99.8  5‘‘ 3.63 (m) 70.3
7 - n.d.  6‘‘ 0.93 (d, 5.8) 18.0
8 6.72 (s) 95.0    
9 - n.d.  Ara    
10 - n.d.  1‘‘‘ 4.16 (d, 5.9) 106.2
1‘ - n.d.  2‘‘‘ 3.36 (m) 71.1
2‘ 7.37 (s) 115.9  3‘‘‘ 3.32 (m) 72.6
3‘ - 164.0  4‘‘‘ 3.58 (br s) 67.8
4‘ - 150.4  5‘‘‘ 3.51 (m), 3.29 (m) 65.8
5‘ 6.89 (d, 7.7) 116.2    
6‘ 7.29 (d, 7.7) 121.4  Glc    
   1‘‘‘‘ 5.06 (d, 6.9) 100.6
   2‘‘‘‘ 3.28 (m) 73.3
   3‘‘‘‘ 3.33 (m) 76.5
   4‘‘‘‘ 3.20 (m) 69.8
   5‘‘‘‘ 3.44 (m) 77.3
   6‘‘‘‘ 3.72 (d, 11.5), 3.48 (m) 60.8
a) Rha = α-L-rhamnopyranosyl; Ara = α -L-arabinopyranosyl; Glc = β-D-glucopyranosyl 
b) 13C NMR shifts derived from HSQC and HMBC data 
c) n.d. not detected 
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Table 2 1H and 13C NMR data of compound 4 in DMSO-d6 
position δH (m, J in Hz) δC b),c)  positiona) δH (m, J in Hz) δCb)
Aglycone      Rha    
2 - 157.4  1‘‘ 5.23 (br s) 101.5
3 - 135.0  2‘‘ 4.06 (br s) 80.8
4 - n.d.  3‘‘ 3.66 (dd, 9.3, 3.2) 70.8
5 - 162.0  4‘‘ 3.15 (dd, 9.5, 9.4) 72.4
6 6.22 (s) 97.6  5‘‘ 3.81 (dq, 10.0, 6.4) 70.7
7 - 164.8  6‘‘ 0.95 (d, 6.4) 17.8
8 6.42 (s) 92.5    
9 - 156.8  Ara    
10 - 104.3  1‘‘‘ 4.09 (d, 6.7) 106.9
1‘ - 119.9  2‘‘‘ 3.31 (dd, 8.9, 6.7) 71.6
2‘ 6.93 (s) 107.9  3‘‘‘ 3.29 (dd, 9.0, 2.9) 73.0
3‘ - 146.5  4‘‘‘ 3.55 (br s)  68.1
4‘ - 137.9  5‘‘‘ 3.44 (dd, 12.0, 2.0), 3.23 (br d, 12.0) 66.2
5‘ -  146.5    
6‘ 6.93 (s) 107.9    
a) Rha = α-L-rhamnopyranosyl, Ara = α -L-arabinopyranosyl  
b) 13C NMR shifts derived from HSQC and HMBC data 
c) n.d. not detected 
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Legends for Figures 
 
Fig. 1 HPLC-PDA-ESIMS of the MeOH extract of B. pinnatum. Top: UV trace (220-400 nm). Bottom: 
ESIMS base peak chromatogram (positive ion mode, m/z 200 - 1500). SunFireTM C18 column, A: 0.1% 
aqueous formic acid and B: MeCN, 5-100% B in A in 30 min, 0.5 mL/min. 
Numbers refer to the isolated compounds 1-11. Letters refer to -linolenoyl lysophosphatidylcholine (a, 
tentative assignment), linoleoyl lysophosphatidylcholine and an isomer (b, c), and palmitoyl 
lysophosphatidylcholine (d), respectively. Peaks at Rt 19.5 and 20.0 min (both m/z 699.7), 22.6 min (m/z 
537.6) and 22.7 (m/z 677.7) could not be identified. The front peak in the UV trace contains large amount 
of malic acid, as revealed by 1H NMR analysis. 
 
Fig. 2 Structures of compounds isolated from B. pinnatum. 
 
Fig. 3 Structures of bufadienolides isolated from B. daigremontianum and detected in B. pinnatum. 
 
Fig. 4 Presence of bufadienolides in the CH2Cl2 soluble fraction of B. pinnatum: HPLC-APCIMS base 
peak chromatogram (positive ion mode, m/z 150 - 1500). SunFireTM C18 column, A: 0.1% aqueous formic 
acid and B: MeCN, 5-100% B in A in 30 min, 0.5 mL/min. Numbers refer to bufadienolides 12-15. * This 
peak (m/z 475.3) was tentatively assigned to bryophyllin C [34]. Peaks at Rt 11.0 min (m/z 197.2) and Rt 
11.3 min (m/z 477.3, 459.3) were not identified. 
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Fig. 1 HPLC-PDA-ESIMS of the MeOH extract of B. pinnatum. Top: UV trace (220-400 nm). Bottom: 
ESIMS base peak chromatogram (positive ion mode, m/z 200 - 1500). SunFireTM C18 column, A: 0.1% 
aqueous formic acid and B: MeCN, 5-100% B in A in 30 min, 0.5 mL/min. 
Numbers refer to the isolated compounds 1-11. Letters refer to -linolenoyl lysophosphatidylcholine (a, 
tentative assignment), linoleoyl lysophosphatidylcholine and an isomer (b, c), and palmitoyl 
lysophosphatidylcholine (d), respectively. Peaks at Rt 19.5 and 20.0 min (both m/z 699.7), 22.6 min (m/z 
537.6) and 22.7 (m/z 677.7) could not be identified. * This peak contains an unidentified flavonoid with 
m/z 507. The front peak in the UV trace contains large amount of malic acid, as revealed by 1H NMR 
analysis. 
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Fig. 2 Structures of compounds isolated from B. pinnatum 
4 R1 = OH, R2 = α-L-Ara (12)-α-L-Rha 
5 R1 = OH, R2 = α-L-Rha 
6 R1 = H, R2 = α-L-Ara (12)-α-L-Rha 
8 R1 = H, R2 = α-L-Rha 
9 R = α-L-Ara (12)-α-L-Rha 
10 R = β-D-Xyl (12)-α-L-Rha 7 R3 = OH 
11 R3 = H 
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Fig. 3 Structures of bufadienolides isolated from B. daigremontianum and detected in B. pinnatum.
12 R1 = Ac, R2 = H  13 R = OH 
14 R1 = H, R2 = Ac  15 R = H 
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Fig. 4 Presence of bufadienolides in the CH2Cl2 soluble fraction of B. pinnatum: HPLC-APCIMS base 
peak chromatogram (positive ion mode, m/z 150 - 1500). SunFireTM C18 column, A: 0.1% aqueous formic 
acid and B: MeCN, 5-100% B in A in 30 min, 0.5 mL/min. Numbers refer to bufadienolides 12-15. * This 
peak (m/z 475.3) was tentatively assigned to bryophyllin C [34]. Peaks at Rt 11.0 min (m/z 197.2) and Rt 
11.3 min (m/z 477.3, 459.3) were not identified. 
 
